Anticancer-agent-231-生命科學(xué)試劑-MCE

Hotline:400-820-3792Inhibitors ? ScreeningLibraries ? Proteinswww.MedChemEAnticanceragent231Cat.No.:HY-162575CASNo.:128519-30-2分子式:C??H??ClN?分子量:375.89作用靶點(diǎn):ERK作用通路:MAPK/ERKPathway;StemCell/Wnt儲(chǔ)存方式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY生物活性Anticanceragent231(化合物P5)是一種酪氨酸蛋白激酶抑制劑，IC50值為3.95μM。Anticanceragent231通過(guò)靶向EGFR-ERK1/2信號(hào)通路抑制三陰乳腺癌(TNBC)細(xì)胞的細(xì)胞活力、細(xì)胞增殖、細(xì)胞遷移和癌癥干性，有望在TNBC疾病治療領(lǐng)域發(fā)揮重要作用[1]。IC50&TargetERK1ERK2體外研究Anticanceragent231(CompoundP5)hasgoodcytotoxicityandinhibitsTNBCcells’viability[1].Anticanceragent231(CompoundP5)(1,2,4μM,14days;1,2,4μM,8days)decreasestheproliferationcapacityofHs578TcellsandMDAMB-231cells[1].Anticanceragent231(CompoundP5)(1,2,4μM,12h)decreasesthemigrationabilityofHs578Tcells[1].Anticanceragent231(CompoundP5)(1,2μM)inhibitstumorstemnessandenhancesthesensitivityofTNBCcellstopaclitaxel[1].Anticanceragent231(CompoundP5)(1,2,4μM;5,10,20μM)inhibitsTNBCcellsbytargetingtheEGFR-ERK1/2axis[1].CellLine:Concentration:IncubationTime:Result:CellViabilityAssay[1].CellLine:Hs578Tcell,MDAMB231cell1/3 MasterofBioactiveMolecules—您身邊的抑制劑大師www.MedChemEConcentration:0-40μMIncubationTime:48hResult:ExhibitedthemostcytotoxiceffectagainstHs578TcellsandMDAMB231cellsCellProliferationAssay[1].CellLine:Hs578TcellConcentration:1,2,4μMIncubationTime:14daysResult:InhibitedthecolonyformationofHs578TcellsCellProliferationAssay[1].CellLine:MDAMB231cellConcentration:5,10,20μMIncubationTime:8daysResult:InhibitedthecolonyformationofMDAMB231cellsCellMigrationAssay[1].CellLine:Hs578TcellConcentration:1,2,4μMIncubationTime:12hResult:InhibitedthemigrationabilityofHs578TcellsWesternBlotAnalysis[1].CellLine:Hs578Tcell,MDAMB231cellConcentration:1,2,4μM;5,10,20μMIncubationTime:48hResult:ReducedtheEGFRexpressionlevelinHs578TandMDAMB231cellsanddeactivatedtheEGFRinMDAMB231cellsREFERENCES2/3 MasterofBioactiveMolecules—您身邊的抑制劑大師www.MedChemESatriyoPB,etal.N-phenylpyrazolinederivativeinhibitscellaggressivenessandenhancespaclitaxelsensitivityoftriplenegativebreastcancercells.SciRep.2024Jun8;14(1):13200.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresear